Hajduk and Greer Nature Reviews Drug Discovery 6 , 211 –219 (March 2007) | doi:10.1038/nrd2220

Oct 15, 2014

10 likes | 157 Views

Hajduk and Greer Nature Reviews Drug Discovery 6 , 211 –219 (March 2007) | doi:10.1038/nrd2220.

Share Presentation

Embed Code

Link

hajduk
1038 nrd2220

fawn

Download Presentation

Hajduk and Greer Nature Reviews Drug Discovery 6 , 211 –219 (March 2007) | doi:10.1038/nrd2220

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Hajduk and Greer Nature Reviews Drug Discovery6, 211–219 (March 2007) | doi:10.1038/nrd2220

DRUG DISCOVERY – NEW DRUG DEVELOPMENT PROCESS

DRUG DISCOVERY – NEW DRUG DEVELOPMENT PROCESS. BY. Dr. BASAVARAJ K. NANJWADE. Department of Pharmaceutics K L E UNIVERSITY JN MEDICAL COLLEGE BELGAUM – 590010 E-mail: bknanjwade@yahoo.co.in. DRUG.

1.49k views • 55 slides

Enhancing the drug discovery pipeline – a perspective on CV drugs

Enhancing the drug discovery pipeline – a perspective on CV drugs. Patrick Vallance Head of Drug Discovery, GSK. New Medicines. A disconnect between discovery and invention?. Scientific publications in biomedicine. R&D Productivity Gap.

387 views • 22 slides

Business Value of SW in Drug Discovery

Business Value of SW in Drug Discovery. Eric Neumann, W3C HCLSIG co-chair Teranode Corporation F2F Cambridge MA. Tox/Efficacy. New Regulatory Issues Confronting Pharmaceuticals. ADME Optim. from Innovation or Stagnation , FDA Report March 2004. Drug Discovery Costs.

302 views • 14 slides

J Kim et al. Nature 000 , 1 - 4 (2013) doi:10.1038/nature 12180

Identification of low-molecular-weight compounds associated with CmoA-mediated Cx-SAM production. J Kim et al. Nature 000 , 1 - 4 (2013) doi:10.1038/nature 12180.

152 views • 1 slides

Aloy et al. Nature Reviews Molecular Cell Biology 7 , 188 â€“ 197 (March 2006) | doi:10.1038/nrm1859.

134 views • 1 slides

H Zhao et al. Nature 000 , 1 - 4 (201 4 ) doi:10.1038/nature 13733

Assembly of CasA and CasB to the six-CasC helix mediated by the unique Asp-Arg/Lys-Trp triad. H Zhao et al. Nature 000 , 1 - 4 (201 4 ) doi:10.1038/nature 13733 Note: This figure is from a near-final version AOP and may change prior to final publication in print/online.

181 views • 1 slides

Drug Discovery & Development

Drug Discovery & Development. PHC 311. LEC. 7 Sunday 7/ 1/ 1435H. There are two important aspects in drug design and drug strategies to improve :. Pharmacodynamics properties: to optimize the interaction of the drug with its target.

812 views • 39 slides

D Li et al. Nature 000 , 1 - 4 (2012) doi:10.1038/nature 12179

Putative active site of DgkA complete with lipid and Mg 2+ -ATP substrates and activating zinc. D Li et al. Nature 000 , 1 - 4 (2012) doi:10.1038/nature 12179.

154 views • 1 slides

JN Moum et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12363

Annual cycles of upper-ocean vertical structure at 0, 140°W over the period 2005–11. JN Moum et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12363.

134 views • 1 slides

D Kraus et al. Nature 508 , 258-262 (2014) doi:10.1038/nature 13198

NNMT expression is increased in WAT and liver of obese and insulin-resistant mice. D Kraus et al. Nature 508 , 258-262 (2014) doi:10.1038/nature 13198.

151 views • 1 slides

OA Sherwood et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12784

NPSG circulation and N* distribution with sample locations. OA Sherwood et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12784.

106 views • 1 slides

Kaye and Krum Nature Reviews Drug Discovery 6 , 127 – 139 (February 2007) | doi:10.1038/nrd2219

Kaye and Krum Nature Reviews Drug Discovery 6 , 127 – 139 (February 2007) | doi:10.1038/nrd2219.

187 views • 1 slides

LDB Evans et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12682

Free subunits capture subunits docked at the export gate through head-to-tail linkage of terminal helices. LDB Evans et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12682.

164 views • 1 slides

Yin et al. Nature Reviews Neuroscience 7 , 464 – 476 (June 2006) | doi:10.1038/nrn1919

Yin et al. Nature Reviews Neuroscience 7 , 464 – 476 (June 2006) | doi:10.1038/nrn1919.

135 views • 1 slides

X Tian et al. Nature 000 , 1-4 (2013) doi:10.1038/nature 12234

Naked mole-rat cells secrete HA of exceptionally high molecular mass. X Tian et al. Nature 000 , 1-4 (2013) doi:10.1038/nature 12234.

120 views • 1 slides

Drug Discovery & Development

Drug Discovery & Development. PHC 311. LEC. 3 Sunday 9/ 11/ 1434H. Drug Optimization: Strategies in drug design I-optimizing drug target interactions.

1.22k views • 33 slides

OL Krivanek et al. Nature 514 , 209 - 212 (201 4 ) doi:10.1038/nature 13870

Profile showing the spatial variation of the vibrational signal. OL Krivanek et al. Nature 514 , 209 - 212 (201 4 ) doi:10.1038/nature 13870.

122 views • 1 slides

PA Northcott et al. Nature 000 , 1 - 7 (201 4 ) doi:10.1038/nature 13379

Recurrent SVs activate the GFI1B proto-oncogene in medulloblastoma. PA Northcott et al. Nature 000 , 1 - 7 (201 4 ) doi:10.1038/nature 13379.

98 views • 1 slides

PA Northcott et al. Nature 000 , 1 - 7 (201 4 ) doi:10.1038/nature 13379

Summary of recurrent SVs identified in GFI1B -activated medulloblastomas. PA Northcott et al. Nature 000 , 1 - 7 (201 4 ) doi:10.1038/nature 13379.

82 views • 1 slides

Martino et al. Nature Reviews Neuroscience 7, 395 – 406 (May 2006) | doi:10.1038/nrn1908

Martino et al. Nature Reviews Neuroscience 7, 395 – 406 (May 2006) | doi:10.1038/nrn1908.

109 views • 1 slides

P van Galen et al. Nature 510 , 268 -272 (2014) doi:10.1038/nature 13228

HSCs are predisposed to UPR-induced apoptosis through PERK–eIF2 a –ATF4–CHOP–GADD34 signalling. P van Galen et al. Nature 510 , 268 -272 (2014) doi:10.1038/nature 13228.

125 views • 1 slides

More Related

Hajduk and Greer Nature Reviews Drug Discovery 6 , 211 –219 (March 2007) | doi:10.1038/nrd2220

Hajduk and Greer Nature Reviews Drug Discovery 6 , 211 –219 (March 2007) | doi:10.1038/nrd2220

Presentation Transcript

DRUG DISCOVERY – NEW DRUG DEVELOPMENT PROCESS

Enhancing the drug discovery pipeline – a perspective on CV drugs

Business Value of SW in Drug Discovery

J Kim et al. Nature 000 , 1 - 4 (2013) doi:10.1038/nature 12180

H Zhao et al. Nature 000 , 1 - 4 (201 4 ) doi:10.1038/nature 13733

Drug Discovery &amp; Development

D Li et al. Nature 000 , 1 - 4 (2012) doi:10.1038/nature 12179

JN Moum et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12363

D Kraus et al. Nature 508 , 258-262 (2014) doi:10.1038/nature 13198

OA Sherwood et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12784

Kaye and Krum Nature Reviews Drug Discovery 6 , 127 – 139 (February 2007) | doi:10.1038/nrd2219

LDB Evans et al. Nature 000 , 1 - 4 (201 3 ) doi:10.1038/nature 12682

Yin et al. Nature Reviews Neuroscience 7 , 464 – 476 (June 2006) | doi:10.1038/nrn1919

X Tian et al. Nature 000 , 1-4 (2013) doi:10.1038/nature 12234

Drug Discovery &amp; Development

OL Krivanek et al. Nature 514 , 209 - 212 (201 4 ) doi:10.1038/nature 13870

PA Northcott et al. Nature 000 , 1 - 7 (201 4 ) doi:10.1038/nature 13379

PA Northcott et al. Nature 000 , 1 - 7 (201 4 ) doi:10.1038/nature 13379

Martino et al. Nature Reviews Neuroscience 7, 395 – 406 (May 2006) | doi:10.1038/nrn1908

P van Galen et al. Nature 510 , 268 -272 (2014) doi:10.1038/nature 13228

Drug Discovery & Development

Drug Discovery & Development